Can THEM6 targeting stop resistance to prostate cancer treatment?
Prostate cancer (PCa) clinical management relies heavily on androgen‐deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non‐resectable PCa eventually relapse and develop fatal castration‐resistant PCa (CRPC). Multiple mechanisms of acquired re...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2022-03-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202115504 |
| _version_ | 1797282865794252800 |
|---|---|
| author | Mrittika Chattopadhyay Doris Germain |
| author_facet | Mrittika Chattopadhyay Doris Germain |
| author_sort | Mrittika Chattopadhyay |
| collection | DOAJ |
| description | Prostate cancer (PCa) clinical management relies heavily on androgen‐deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non‐resectable PCa eventually relapse and develop fatal castration‐resistant PCa (CRPC). Multiple mechanisms of acquired resistance to treatment have been reported, including metabolic adaptation (Marine et al, 2020). Notably, activation of the endoplasmic reticulum (ER) unfolded protein response (UPR) has been associated with oncogenic transformation (Hart et al, 2012), tumor progression, metastasis dissemination, and resistance to therapy (Chen & Cubillos‐Ruiz, 2021). Targeting different branches of ER UPR has been found to be an effective tool against aggressive PCa (Nguyen et al, 2018; Sheng et al, 2019). Therefore, a better understanding of these pathways may lead to the identification of novel drug targets. |
| first_indexed | 2024-03-07T17:19:38Z |
| format | Article |
| id | doaj.art-f13114d0fdfd4579ae503e0eb5d82023 |
| institution | Directory Open Access Journal |
| issn | 1757-4676 1757-4684 |
| language | English |
| last_indexed | 2024-03-07T17:19:38Z |
| publishDate | 2022-03-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj.art-f13114d0fdfd4579ae503e0eb5d820232024-03-02T20:52:36ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842022-03-01143n/an/a10.15252/emmm.202115504Can THEM6 targeting stop resistance to prostate cancer treatment?Mrittika Chattopadhyay0Doris Germain1Tish Cancer Institute Division of Hematology/Oncology Icahn School of Medicine at Mount Sinai New York NY USATish Cancer Institute Division of Hematology/Oncology Icahn School of Medicine at Mount Sinai New York NY USAProstate cancer (PCa) clinical management relies heavily on androgen‐deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non‐resectable PCa eventually relapse and develop fatal castration‐resistant PCa (CRPC). Multiple mechanisms of acquired resistance to treatment have been reported, including metabolic adaptation (Marine et al, 2020). Notably, activation of the endoplasmic reticulum (ER) unfolded protein response (UPR) has been associated with oncogenic transformation (Hart et al, 2012), tumor progression, metastasis dissemination, and resistance to therapy (Chen & Cubillos‐Ruiz, 2021). Targeting different branches of ER UPR has been found to be an effective tool against aggressive PCa (Nguyen et al, 2018; Sheng et al, 2019). Therefore, a better understanding of these pathways may lead to the identification of novel drug targets.https://doi.org/10.15252/emmm.202115504 |
| spellingShingle | Mrittika Chattopadhyay Doris Germain Can THEM6 targeting stop resistance to prostate cancer treatment? EMBO Molecular Medicine |
| title | Can THEM6 targeting stop resistance to prostate cancer treatment? |
| title_full | Can THEM6 targeting stop resistance to prostate cancer treatment? |
| title_fullStr | Can THEM6 targeting stop resistance to prostate cancer treatment? |
| title_full_unstemmed | Can THEM6 targeting stop resistance to prostate cancer treatment? |
| title_short | Can THEM6 targeting stop resistance to prostate cancer treatment? |
| title_sort | can them6 targeting stop resistance to prostate cancer treatment |
| url | https://doi.org/10.15252/emmm.202115504 |
| work_keys_str_mv | AT mrittikachattopadhyay canthem6targetingstopresistancetoprostatecancertreatment AT dorisgermain canthem6targetingstopresistancetoprostatecancertreatment |